Art. -Nr.: HY-50001

Nucleozin

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

Nucleozin, a potent inhibitor of influenza A virus infection, induces the formation of nucleoprotein (NP) aggregates and antagonizes its nuclear accumulation, leading to cessation of viral replication. Nucleozin impedes influenza A virus replication in vitro with a nanomolar EC₅₀.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.66%
CAS. Nr.: 341001-38-5
Formel: C₂₁H₁₉ClN₄O₄
Molecular Weight:426.85

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Nucleozin Chemical Structure

CAS. Nr.: 341001-38-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

GSPT1

Cellular Effect

Cell Line	Type	Value	Description	References
MDCK	CC₅₀	>80 μM Compound: Nucleozin	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by CellTiter-Glo assay	[PMID: 25147619]
MDCK	CC₅₀	15.9 μM Compound: 1	Cytotoxicity against MDCK cells after 3 days by CCK-8 assay Cytotoxicity against MDCK cells after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	EC₅₀	0.71 μM Compound: Nucleozin	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytocidal activity after 48 hrs by CellTiter-Glo assay	[PMID: 25147619]
MDCK	IC₅₀	>100 μM Compound: 1	Antiviral activity against Influenza A virus A/New Jersey/8/76 (H1N1) expressing NP Y289H mutant infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/New Jersey/8/76 (H1N1) expressing NP Y289H mutant infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	>50 μM Compound: 1	Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) harboring nucleoprotein 52H mutant infected in MDCK cells assessed as reduction of nucleoprotein antigen level after 3 days Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) harboring nucleoprotein 52H mutant infected in MDCK cells assessed as reduction of nucleoprotein antigen level after 3 days	[PMID: 22332894]
MDCK	IC₅₀	0.1 μM Compound: 1	Antiviral activity against amantidine-resistant Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as reduction in plaque formation after 3 days by microplate counting of infectious particles assay Antiviral activity against amantidine-resistant Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as reduction in plaque formation after 3 days by microplate counting of infectious particles assay	[PMID: 22332894]
MDCK	IC₅₀	0.15 μM Compound: 1	Antiviral activity against Influenza A virus A/RG14 (H5N1) harboring hemagglutininin and neuraminidase genes from Influenza A virus A/VietNam/1194/2004 and other influenza genes from PR8 viruses infected in MDCK cells assessed as inhibition of virus-induc Antiviral activity against Influenza A virus A/RG14 (H5N1) harboring hemagglutininin and neuraminidase genes from Influenza A virus A/VietNam/1194/2004 and other influenza genes from PR8 viruses infected in MDCK cells assessed as inhibition of virus-induc	[PMID: 22332894]
MDCK	IC₅₀	0.2 μM Compound: 1	Antiviral activity against Influenza A virus A/Weiss/43 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/Weiss/43 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	0.32 μM Compound: 1	Antiviral activity against amantidine-resistant Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against amantidine-resistant Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	0.34 μM Compound: 1	Antiviral activity against Influenza A virus A/udorn/1972 (H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/udorn/1972 (H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	0.49 μM Compound: 1	Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) harboring wild type nucleoprotein 52Y infected in MDCK cells assessed as reduction of nucleoprotein antigen level after 3 days Antiviral activity against Influenza A virus A/WSN/1933 (H1N1) harboring wild type nucleoprotein 52Y infected in MDCK cells assessed as reduction of nucleoprotein antigen level after 3 days	[PMID: 22332894]
MDCK	IC₅₀	0.52 μM Compound: 1	Antiviral activity against Influenza A virus A/Mal/302/54 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/Mal/302/54 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	0.54 μM Compound: 1	Antiviral activity against Influenza A virus A/Guangzhou/2009 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/Guangzhou/2009 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	0.66 μM Compound: 1	Antiviral activity against tamiflu-resistant Influenza A virus A/WSN/33 (H1N1) harboring neuraminidase 274Y mutant infected in MDCK cells assessed as reduction of nucleoprotein antigen level after 3 days Antiviral activity against tamiflu-resistant Influenza A virus A/WSN/33 (H1N1) harboring neuraminidase 274Y mutant infected in MDCK cells assessed as reduction of nucleoprotein antigen level after 3 days	[PMID: 22332894]
MDCK	IC₅₀	1.08 μM Compound: 1	Antiviral activity against Influenza A virus A/HK/8/68(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/HK/8/68(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	1.59 μM Compound: 1	Antiviral activity against Influenza A virus A/Brisbane/10/2007 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/Brisbane/10/2007 (H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	12.4 μM Compound: 1	Antiviral activity against Influenza A virus A/Brisbane/10/2007 (H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/Brisbane/10/2007 (H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]
MDCK	IC₅₀	3.87 μM Compound: 1	Antiviral activity against Influenza A virus A/Guangdong/96 (H9N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay Antiviral activity against Influenza A virus A/Guangdong/96 (H9N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effects after 3 days by CCK-8 assay	[PMID: 22332894]

In Vitro

Nucleozin inhibits infection of MDCK cells by the viruses influenza A/WSN/33, H3N2 and Vietnam/1194/04 (H5N1) with an EC₅₀ of 0.069 μM, 0.16 μM and 0.33 μM in plaque reduction assay (PRA) , respectively, severely suppresses viral growth at 0.1 μM and totally inhibites virus production at 1 μM in multicycle growth assays^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Nucleozin protectes mice challenged with lethal doses of avian influenza A H5N1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 341001-38-5
Appearance Solid
Molecular Weight 426.85
Formel C₂₁H₁₉ClN₄O₄
Color Light yellow to yellow
SMILES

CC1=C(C(C2=CC=CC=C2)=NO1)C(N3CCN(C4=C(C=C(C=C4)[N+]([O-])=O)Cl)CC3)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All IF

Sort by:

Journal Impact Factor

Nat Commun

Myoferlin is a component of late-stage vRNP trafficking vesicles for enveloped RNA viruses. [Abstract]

2026 Feb 7. PMID: 41654495
Arch Pharm Res

Germacrane and humulane sesquiterpenes from the roots and rhizomes of Valeriana officinalis var. latifolia and their anti-inflammatory and anti-influenza virus activities. [Abstract]

2025 Sep 25. PMID: 40999190
J Agric Food Chem

Biotransformation of Patchouli Alcohol by Cladosporium cladosporioides and the Anti-Influenza Virus Activities of Biotransformation Products. [Abstract]

2024 Apr 10;72(14):7991-8005. PMID: 38544458
Antiviral Res

Cryptoporic acid E from Cryptoporus volvatus inhibits influenza virus replication in vitro. [Abstract]

2017 Jul:143:106-112. PMID: 28232246

Nucleozin purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2017 Jul:143:106-112. [Abstract]

MDCK cells are infected with H1N1/09pdm at an MOI of 10 in the presence of DMSO, CAE (60 μM) or Nucleozin (1 μM). At 3 h later, cells are fixed by 4% paraformaldehyde and NP is detected by IFA. Nuclei are stained with DAPI. Immunofluorescence is observed with a Nikon A1 confocal microscope.
Phytochemistry

Pogocablenes A-O, fifteen undescribed sesquiterpenoids with structural diversity from Pogostemon cablin. [Abstract]

2023 Oct:214:113829. PMID: 37597718
Fitoterapia

Aromadendrane and alloaromedendrane-type sesquiterpenoids from the roots and rhizomes of Valeriana officinalis var. latifolia and their biological activities. [Abstract]

2026 Apr:190:107144. PMID: 41707879
Biochem Biophys Res Commun

Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity. [Abstract]

2014 Jul 18;450(1):49-54. PMID: 24858693
bioRxiv

2024 July 02.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 20 mg/mL (46.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3427 mL

11.7137 mL

23.4274 mL

5 mM

0.4685 mL

2.3427 mL

4.6855 mL

10 mM

0.2343 mL

1.1714 mL

2.3427 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2 mg/mL (4.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2 mg/mL (4.69 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kao RY, et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol. 2010;28(6):600-605. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3427 mL	11.7137 mL	23.4274 mL	58.5686 mL
	5 mM	0.4685 mL	2.3427 mL	4.6855 mL	11.7137 mL
	10 mM	0.2343 mL	1.1714 mL	2.3427 mL	5.8569 mL
	15 mM	0.1562 mL	0.7809 mL	1.5618 mL	3.9046 mL
	20 mM	0.1171 mL	0.5857 mL	1.1714 mL	2.9284 mL
	25 mM	0.0937 mL	0.4685 mL	0.9371 mL	2.3427 mL
	30 mM	0.0781 mL	0.3905 mL	0.7809 mL	1.9523 mL
	40 mM	0.0586 mL	0.2928 mL	0.5857 mL	1.4642 mL

Keywords

Nucleozin

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Nucleozin

Anti-Infection Compound Library

Antiviral Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Nucleozin

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Nucleozin

Anti-Infection Compound Library

Antiviral Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Nucleozin

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Nucleozin Related Classifications

HY-50001 Related Classifications